ATAMYO THERAPEUTICS
Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. The company was founded in 2020 by Stephane Degove and Isabelle Richard and its headquarters is located in Paris, France.
ATAMYO THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Medical Neuroscience
Founded:
2020-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.atamyo.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving Google Maps ReCAPTCHA French Server Location
Similar Organizations
ALPHELYS
ALPHELYS designs and develops instruments, software, and reagents for pathology and cytogenetics markets.
Dolomite Bio
Dolomite Bio is a bio-research firm that offers single-cell research by encapsulating single cells in microfluidic droplets.
Foldrx Pharmaceuticals
FoldRx Pharmaceuticals is focused on discovering and developing disease-modifying drug therapies for protein misfolding diseases.
Neurometry
Neurometry focuses on the development of technologies for building a neuroscience telemedicine platform.
ptTheragnostic
ptTheragnostic focuses on the development of genomics-based personalized analysis for radiation sensitivity.
Strominnate Therapeutics
Strominnate Therapeutics is the pioneer in the development of a new era for treating tumors and conditions of the nervous system.
SynBioVen
SynBioVen is focused on supporting the next generation of synthetic biology scientists, founders and start-ups.
Current Employees Featured
Official Site Inspections
http://www.atamyo.com Semrush global rank: 15.46 M Semrush visits lastest month: 3
- Host name: vps-e8067df7.vps.ovh.net
- IP address: 37.187.179.92
- Location: Paris France
- Latitude: 48.8543
- Longitude: 2.3527
- Timezone: Europe/Paris
- Postal: 75000
More informations about "Atamyo Therapeutics"
Atamyo | Gene Therapy for LGMD Patients
Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 Atamyo has …See details»
Atamyo Therapeutics - Crunchbase Company Profile
Organization. Atamyo Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
The Dion Foundation and Atamyo Therapeutics Announce a …
Sep 4, 2024 The US-based Dion Foundation is a non-profit organization devoted to increasing awareness and allocating funds towards research and development of potential treatments of …See details»
Atamyo Therapeutic - Dion Foundation for Children with Rare …
Atamyo is a spin-off of Genethon, a non-profit research organization that is a pioneer in developing gene therapies for rare diseases. ATA-200 is based on the research of Atamyo …See details»
The Dion Foundation and Atamyo Therapeutics Announce a …
Atamyo is a spin-off of Genethon, a non-profit research organization that is a pioneer in developing gene therapies for rare diseases. ATA-200 is based on the research of Atamyo …See details»
Atamyo Therapeutics SAS - Drug pipelines, Patents, Clinical trials ...
PARIS--(BUSINESS WIRE)-- Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), provided updates in …See details»
Atamyo Therapeutics - Funding, Financials, Valuation & Investors
Jul 15, 2024 Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. New. Resources. ... How much …See details»
Atamyo Therapeutics - healthtechinnovationdays6.com
Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD2I/R9 and LGMD2C/R5. …See details»
A patient advocacy group founded by two parents has partnered …
Nov 19, 2024 Dion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support …See details»
Atamyo Therapeutics - Contacts, Employees, Board Members
Organization. Atamyo Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. …See details»
The Dion Foundation and Atamyo Therapeutics Announce a …
2 days ago The US-based Dion Foundation is a non-profit organization devoted to increasing awareness and allocating funds towards research and development of potential treatments of …See details»
Atamyo Therapeutics Announces Key Scientific Communications …
“This unique track record shows the scientific leadership of Atamyo and its parent organization Genethon in the development of disruptive gene therapies targeting LGMDs. These …See details»
Atamyo Therapeutics - VentureRadar
Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD). Limb girdle muscular dystrophies (LGMDs) are a group of rare genetic disorders …See details»
Atamyo Therapeutics 2025 Company Profile: Valuation, Funding ...
Atamyo Therapeutics was founded in 2020. Where is Atamyo Therapeutics headquartered? Atamyo Therapeutics is headquartered in Evry, France. What industry is Atamyo Therapeutics …See details»
Atamyo - 2025 Company Profile & Competitors - Tracxn
3 days ago Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and EuropeBusiness Wire • Sep 16, 2024 • …See details»
ATAMYO THERAPEUTICS - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Atamyo’s …See details»
History - Atamyo Therapeutics
Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD). 2020. Genethon has been a pioneer in gene therapy for the last 30 years. …See details»
Atamyo Therapeutics - EU-Startups
Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. The company was founded in 2020 by Stephane …See details»
Atamyo Therapeutics Hits Milestones for Limb-Girdle Muscular …
Sep 30, 2024 Atamyo Therapeutics has finished recruiting patients for the dose escalation portion of its phase 1b ATA-001-FKRP clinical trial (NCT05224505) evaluating ATA-100, an …See details»
Atamyo Therapeutics franchit d'importantes étapes réglementaires …
D'Atamyo, directrice de recherche au CNRS et responsable du laboratoire des Dystrophies musculaires progressives de Généthon. À propos d’Atamyo Therapeutics Atamyo …See details»